FindTrial
Sign In

A study on how AI and doctors agree on safe medicines and doses for ICU patients

An Observational Longitudinal Study to Explore the Concordance between an Advanced Generative AI Model, Live Clinical Prescription, and a Gold Standard Prescription of Drug Appropriateness, Dosing, and Drug-Drug Interactions in a Medical ICU. - AIM-ICU (AI in Medication Safety ICU Study)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/095710
Enrollment
50
Registered
2025-10-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: B999- Unspecified infectious disease

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Medanta- The Medicity
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult patients admitted to the Medical ICU at Medanta The Medicity with ICU stay more than or equal to 6 hours whose retrospective prescription data is available through eHIS for at least 5 days

Exclusion criteria

Exclusion criteria: ICU stay less than 6 hours Patients admitted with poisoning or snake bite Trauma patients

Design outcomes

Primary

MeasureTime frame
Number and severity of clinically significant DDIsTimepoint: Within 5 days of ICU stay (daily prescription review)—

Secondary

MeasureTime frame
Instances of inappropriate drug, dose, frequency, or duration. Concordance rates between AI, live clinician and gold standard Timepoint: Within 5 days of ICU stay (daily prescription review)—

Countries

India

Contacts

Public ContactDr Sushila Kataria

Medanta The Medicity

Sushila.Kataria@medanta.org9818828078

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026